Tomioka A - Search Results

1

GFP image analysis in the mouse orthotopic bladder cancer model.

De Velasco MA, Tanaka M, Anai S, Tomioka A, Nishio K, Uemura H. De Velasco MA, et al. Among authors: tomioka a. Oncol Rep. 2008 Sep;20(3):543-7. Oncol Rep. 2008. PMID: 18695904

2

Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation.

Tomioka A, Tanaka M, De Velasco MA, Anai S, Takada S, Kushibiki T, Tabata Y, Rosser CJ, Uemura H, Hirao Y. Tomioka A, et al. Mol Cancer Ther. 2008 Jul;7(7):1864-70. doi: 10.1158/1535-7163.MCT-07-2198. Mol Cancer Ther. 2008. PMID: 18644998

3

PTEN knockout prostate cancer as a model for experimental immunotherapy.

Haga K, Tomioka A, Liao CP, Kimura T, Matsumoto H, Ohno I, Hermann K, Logg CR, Jiao J, Tanaka M, Hirao Y, Wu H, Kruse CA, Roy-Burman P, Kasahara N. Haga K, et al. Among authors: tomioka a. J Urol. 2009 Jan;181(1):354-62. doi: 10.1016/j.juro.2008.08.124. Epub 2008 Nov 17. J Urol. 2009. PMID: 19010487 Free PMC article.

4

Inhibition of heme oxygenase-1 enhances the cytotoxic effect of gemcitabine in urothelial cancer cells.

Miyake M, Fujimoto K, Anai S, Ohnishi S, Nakai Y, Inoue T, Matsumura Y, Tomioka A, Ikeda T, Okajima E, Tanaka N, Hirao Y. Miyake M, et al. Among authors: tomioka a. Anticancer Res. 2010 Jun;30(6):2145-52. Anticancer Res. 2010. PMID: 20651363

5

Clinical significance of heme oxygenase-1 expression in non-muscle-invasive bladder cancer.

Miyake M, Fujimoto K, Anai S, Ohnishi S, Nakai Y, Inoue T, Matsumura Y, Tomioka A, Ikeda T, Tanaka N, Hirao Y. Miyake M, et al. Among authors: tomioka a. Urol Int. 2010;85(3):355-63. doi: 10.1159/000317785. Epub 2010 Aug 21. Urol Int. 2010. PMID: 20733275

6

Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladder.

Miyake M, Fujimoto K, Anai S, Ohnishi S, Kuwada M, Nakai Y, Inoue T, Matsumura Y, Tomioka A, Ikeda T, Tanaka N, Hirao Y. Miyake M, et al. Among authors: tomioka a. Oncol Rep. 2011 Mar;25(3):653-60. doi: 10.3892/or.2010.1125. Epub 2010 Dec 27. Oncol Rep. 2011. PMID: 21206978

7

Calculated tumor volume is an independent predictor of biochemical recurrence in patients who underwent retropubic radical prostatectomy.

Tanaka N, Fujimoto K, Hirayama A, Nakai Y, Chihara Y, Anai S, Tomioka A, Shimada K, Konishi N, Hirao Y. Tanaka N, et al. Among authors: tomioka a. Adv Urol. 2012;2012:204215. doi: 10.1155/2012/204215. Epub 2012 May 13. Adv Urol. 2012. PMID: 22654901 Free PMC article.

8

5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma.

Miyake M, Anai S, Fujimoto K, Ohnishi S, Kuwada M, Nakai Y, Inoue T, Tomioka A, Tanaka N, Hirao Y. Miyake M, et al. Among authors: tomioka a. Oncol Lett. 2012 Jun;3(6):1195-1202. doi: 10.3892/ol.2012.662. Epub 2012 Mar 29. Oncol Lett. 2012. PMID: 22783417 Free PMC article.

9

Phosphorylation status of Fas-associated death domain protein is associated with biochemical recurrence after radical prostatectomy.

Ikeda T, Tanaka N, Shimada K, Matsumura Y, Miyake M, Anai S, Tomioka A, Okajima E, Hirayama A, Fujimoto K, Konishi N, Hirao Y. Ikeda T, et al. Among authors: tomioka a. Urology. 2013 Mar;81(3):607-10. doi: 10.1016/j.urology.2012.11.032. Epub 2013 Jan 24. Urology. 2013. PMID: 23352370

10

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer.

Tomioka A, Tanaka N, Yoshikawa M, Miyake M, Anai S, Chihara Y, Okajima E, Hirayama A, Hirao Y, Fujimoto K. Tomioka A, et al. BMC Urol. 2014 Apr 29;14:33. doi: 10.1186/1471-2490-14-33. BMC Urol. 2014. PMID: 24773608 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

137 results

Search Page

Filters